Benzinga | Aug 6, 2020 07:19AM EDT

Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 29.41 percent increase over losses of $(0.34) per share from the same period last year.